Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral Studies. Benvenutti, R., Gallas-Lopes, M., Marcon, M., Reschke, C. R., Herrmann, A. P., & Piato, A. Current Neuropharmacology, 20(3):494–509. ![Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral Studies [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper abstract bibtex Schizophrenia pathophysiology is associated with hypofunction of glutamate NMDA receptors (NMDAR) in GABAergic interneurons and dopaminergic hyperactivation in subcortical brain areas. The administration of NMDAR antagonists is used as an animal model that replicates behavioral phenotypes relevant to the positive, negative, and cognitive symptoms of schizophrenia. Such models overwhelmingly rely on rodents, which may lead to species-specific biases and poor translatability. Zebrafish, however, is increasingly used as a model organism to study evolutionarily conserved aspects of behavior. We thus aimed to review and integrate the major findings reported in the zebrafish literature regarding the behavioral effects of NMDAR antagonists with relevance to schizophrenia. We identified 44 research articles that met our inclusion criteria from 590 studies retrieved from MEDLINE (PubMed) and Web of Science databases. Dizocilpine (MK-801) and ketamine were employed in 29 and 10 studies, respectively. The use of other NMDAR antagonists, such as phencyclidine (PCP), APV, memantine, and tiletamine, was described in 6 studies. Frequently reported findings are the social interaction and memory deficits induced by MK-801 and circling behavior induced by ketamine. However, mixed results were described for several locomotor and exploratory parameters in the novel tank and open tank tests. The present review integrates the most relevant results while discussing variation in experimental design and methodological procedures. We conclude that zebrafish is a suitable model organism to study drug-induced behavioral phenotypes relevant to schizophrenia. However, more studies are necessary to further characterize the major differences in behavior as compared to mammals.
@article{benvenutti_glutamate_nodate,
title = {Glutamate {NMDA} {Receptor} {Antagonists} with {Relevance} to {Schizophrenia}: {A} {Review} of {Zebrafish} {Behavioral} {Studies}},
volume = {20},
shorttitle = {Glutamate {NMDA} {Receptor} {Antagonists} with {Relevance} to {Schizophrenia}},
url = {https://www.eurekaselect.com/article/114206},
abstract = {Schizophrenia pathophysiology is associated with hypofunction of glutamate NMDA
receptors (NMDAR) in GABAergic interneurons and dopaminergic hyperactivation in subcortical
brain areas. The administration of NMDAR antagonists is used as an animal model that replicates
behavioral phenotypes relevant to the positive, negative, and cognitive symptoms of schizophrenia.
Such models overwhelmingly rely on rodents, which may lead to species-specific biases and poor
translatability. Zebrafish, however, is increasingly used as a model organism to study evolutionarily
conserved aspects of behavior. We thus aimed to review and integrate the major findings reported
in the zebrafish literature regarding the behavioral effects of NMDAR antagonists with relevance to
schizophrenia. We identified 44 research articles that met our inclusion criteria from 590 studies
retrieved from MEDLINE (PubMed) and Web of Science databases. Dizocilpine (MK-801) and
ketamine were employed in 29 and 10 studies, respectively. The use of other NMDAR antagonists,
such as phencyclidine (PCP), APV, memantine, and tiletamine, was described in 6 studies. Frequently
reported findings are the social interaction and memory deficits induced by MK-801 and
circling behavior induced by ketamine. However, mixed results were described for several locomotor
and exploratory parameters in the novel tank and open tank tests. The present review integrates
the most relevant results while discussing variation in experimental design and methodological
procedures. We conclude that zebrafish is a suitable model organism to study drug-induced behavioral
phenotypes relevant to schizophrenia. However, more studies are necessary to further characterize
the major differences in behavior as compared to mammals.},
language = {en},
number = {3},
urldate = {2023-12-25},
journal = {Current Neuropharmacology},
author = {Benvenutti, Radharani and Gallas-Lopes, Matheus and Marcon, Matheus and Reschke, Cristina R. and Herrmann, Ana Paula and Piato, Angelo},
keywords = {nmda},
pages = {494--509},
}
Downloads: 0
{"_id":"dhq8DAwaWmWQjGHnS","bibbaseid":"benvenutti-gallaslopes-marcon-reschke-herrmann-piato-glutamatenmdareceptorantagonistswithrelevancetoschizophreniaareviewofzebrafishbehavioralstudies","author_short":["Benvenutti, R.","Gallas-Lopes, M.","Marcon, M.","Reschke, C. R.","Herrmann, A. P.","Piato, A."],"bibdata":{"bibtype":"article","type":"article","title":"Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral Studies","volume":"20","shorttitle":"Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia","url":"https://www.eurekaselect.com/article/114206","abstract":"Schizophrenia pathophysiology is associated with hypofunction of glutamate NMDA receptors (NMDAR) in GABAergic interneurons and dopaminergic hyperactivation in subcortical brain areas. The administration of NMDAR antagonists is used as an animal model that replicates behavioral phenotypes relevant to the positive, negative, and cognitive symptoms of schizophrenia. Such models overwhelmingly rely on rodents, which may lead to species-specific biases and poor translatability. Zebrafish, however, is increasingly used as a model organism to study evolutionarily conserved aspects of behavior. We thus aimed to review and integrate the major findings reported in the zebrafish literature regarding the behavioral effects of NMDAR antagonists with relevance to schizophrenia. We identified 44 research articles that met our inclusion criteria from 590 studies retrieved from MEDLINE (PubMed) and Web of Science databases. Dizocilpine (MK-801) and ketamine were employed in 29 and 10 studies, respectively. The use of other NMDAR antagonists, such as phencyclidine (PCP), APV, memantine, and tiletamine, was described in 6 studies. Frequently reported findings are the social interaction and memory deficits induced by MK-801 and circling behavior induced by ketamine. However, mixed results were described for several locomotor and exploratory parameters in the novel tank and open tank tests. The present review integrates the most relevant results while discussing variation in experimental design and methodological procedures. We conclude that zebrafish is a suitable model organism to study drug-induced behavioral phenotypes relevant to schizophrenia. However, more studies are necessary to further characterize the major differences in behavior as compared to mammals.","language":"en","number":"3","urldate":"2023-12-25","journal":"Current Neuropharmacology","author":[{"propositions":[],"lastnames":["Benvenutti"],"firstnames":["Radharani"],"suffixes":[]},{"propositions":[],"lastnames":["Gallas-Lopes"],"firstnames":["Matheus"],"suffixes":[]},{"propositions":[],"lastnames":["Marcon"],"firstnames":["Matheus"],"suffixes":[]},{"propositions":[],"lastnames":["Reschke"],"firstnames":["Cristina","R."],"suffixes":[]},{"propositions":[],"lastnames":["Herrmann"],"firstnames":["Ana","Paula"],"suffixes":[]},{"propositions":[],"lastnames":["Piato"],"firstnames":["Angelo"],"suffixes":[]}],"keywords":"nmda","pages":"494–509","bibtex":"@article{benvenutti_glutamate_nodate,\n\ttitle = {Glutamate {NMDA} {Receptor} {Antagonists} with {Relevance} to {Schizophrenia}: {A} {Review} of {Zebrafish} {Behavioral} {Studies}},\n\tvolume = {20},\n\tshorttitle = {Glutamate {NMDA} {Receptor} {Antagonists} with {Relevance} to {Schizophrenia}},\n\turl = {https://www.eurekaselect.com/article/114206},\n\tabstract = {Schizophrenia pathophysiology is associated with hypofunction of glutamate NMDA\nreceptors (NMDAR) in GABAergic interneurons and dopaminergic hyperactivation in subcortical\nbrain areas. The administration of NMDAR antagonists is used as an animal model that replicates\nbehavioral phenotypes relevant to the positive, negative, and cognitive symptoms of schizophrenia.\nSuch models overwhelmingly rely on rodents, which may lead to species-specific biases and poor\ntranslatability. Zebrafish, however, is increasingly used as a model organism to study evolutionarily\nconserved aspects of behavior. We thus aimed to review and integrate the major findings reported\nin the zebrafish literature regarding the behavioral effects of NMDAR antagonists with relevance to\nschizophrenia. We identified 44 research articles that met our inclusion criteria from 590 studies\nretrieved from MEDLINE (PubMed) and Web of Science databases. Dizocilpine (MK-801) and\nketamine were employed in 29 and 10 studies, respectively. The use of other NMDAR antagonists,\nsuch as phencyclidine (PCP), APV, memantine, and tiletamine, was described in 6 studies. Frequently\nreported findings are the social interaction and memory deficits induced by MK-801 and\ncircling behavior induced by ketamine. However, mixed results were described for several locomotor\nand exploratory parameters in the novel tank and open tank tests. The present review integrates\nthe most relevant results while discussing variation in experimental design and methodological\nprocedures. We conclude that zebrafish is a suitable model organism to study drug-induced behavioral\nphenotypes relevant to schizophrenia. However, more studies are necessary to further characterize\nthe major differences in behavior as compared to mammals.},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2023-12-25},\n\tjournal = {Current Neuropharmacology},\n\tauthor = {Benvenutti, Radharani and Gallas-Lopes, Matheus and Marcon, Matheus and Reschke, Cristina R. and Herrmann, Ana Paula and Piato, Angelo},\n\tkeywords = {nmda},\n\tpages = {494--509},\n}\n\n\n\n","author_short":["Benvenutti, R.","Gallas-Lopes, M.","Marcon, M.","Reschke, C. R.","Herrmann, A. P.","Piato, A."],"key":"benvenutti_glutamate_nodate","id":"benvenutti_glutamate_nodate","bibbaseid":"benvenutti-gallaslopes-marcon-reschke-herrmann-piato-glutamatenmdareceptorantagonistswithrelevancetoschizophreniaareviewofzebrafishbehavioralstudies","role":"author","urls":{"Paper":"https://www.eurekaselect.com/article/114206"},"keyword":["nmda"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/sumbre","dataSources":["FTTT6MtwhkNF2aJCF"],"keywords":["nmda"],"search_terms":["glutamate","nmda","receptor","antagonists","relevance","schizophrenia","review","zebrafish","behavioral","studies","benvenutti","gallas-lopes","marcon","reschke","herrmann","piato"],"title":"Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral Studies","year":null}